Open-Label Long-Term Extension Study of QRX003 Lotion in Participants with Netherton Syndrome

• Research type

  Research Study

• Full title

  Multicenter, Open-Label, Long-Term Extension Study of QRX003 Lotion in Participants with Netherton Syndrome

• IRAS ID

  1014210

• Contact name

  Michael Myers

• Contact email

  mmyers@quoinpharma.com

• Sponsor organisation

  Quoin Therapeutics (Ireland) Limited

• Research summary

  The study will assess the long-term safety and efficacy of a novel Investigational Medicinal Product (IMP) QRX003 (dipalmitoyl hydroxyproline) skin lotion in participants with Netherton Syndrome (NS). The QRX003 lotion 4% will be applied twice daily (BID).
  The study will enroll 10 male and female participants 4 years of age or older with NS, who participated in a previous study of 4% QRX003 lotion (CL-QRX003-002, CL-QRX003-004, or CL-QRX003-005). The patients will have 12 months treatment.
  Participants will require to complete 6 study visits: Screening, Baseline, Month 3, Month 6, Month 9 and Month 12.

• REC name

  London - Hampstead Research Ethics Committee

• REC reference

  26/LO/0447

• Date of REC Opinion

  16 Jun 2026

• REC opinion

  Further Information Favourable Opinion